Haemonetics Corporation HAE
NYSE · United States · Health Technology
$105.30-0.50 (-0.47%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, November 5, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 5, 2026.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Haemonetics (HAE) has been drawing investor attention after a strong total return over the past year, along with double-digit annual growth in both revenue and net income. Despite a small dip in the latest session, Haemonetics’ share price is US$108.52, with a strong 90 day share price return of 48.92% and a 1 year total shareholder return of 114.25%. This points to momentum building as investors reassess growth prospects and risk. Scan Haemonetics’ momentum against peers and uncover other...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.